Cited by 40NF-κB Signaling PathwaysSignaling Pathways in DiseasePI3K/AKT/mTOR signaling in cancer

AKT Activation by Pdcd4 Knockdown Up-Regulates Cyclin D1 Expression and Promotes Cell Proliferation

Open access
Guo, X., Li, W., Wang, Q., Yang, H.-S.·2011·Genes & Cancer

Abstract

Programmed cell death 4 (Pdcd4), a novel tumor suppressor, inhibits neoplastic transformation and tumor invasion. In this study, the authors found that knockdown of Pdcd4 promoted cell proliferation and up-regulated cyclin D1 expression. Previously, the authors demonstrated that Pdcd4 knockdown activated NF-κB-dependent transcription. Mutations of NF-κB binding sites on the cyclin D1 promoter attenuated the cyclin D1 promoter activity induced by Pdcd4 knockdown. In addition, knockdown of NF-κB/IκB kinase (IKK) α or IKKβ, the kinase regulating NF-κB activation, inhibited cyclin D1 promoter activity and cyclin D1 expression, indicating that up-regulation of cyclin D1 by Pdcd4 knockdown is contributed, at least in part, by NF-κB activation. To investigate the mechanism of how Pdcd4 knockdown activates NF-κB, the authors found that the levels of AKT phosphorylation and AKT kinase activity were increased in the Pdcd4 knockdown cells. Conversely, ectopic expression of Pdcd4 inhibited AKT phosphorylation and cyclin D1 expression, suggesting that Pdcd4 regulates AKT activity and cyclin D1 expression. Furthermore, knockdown of AKT in the Pdcd4 knockdown cells inhibited IKK phosphorylation, NF-κB activation, cyclin D1 promoter activity, and cyclin D1 expression as well as cell proliferation. Taken together, these findings suggest that activation of NF-κB by Pdcd4 knockdown through AKT contributes to the elevated expression of cyclin D1, thus providing new insights into how loss of Pdcd4 expression promotes tumor development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1947601911431082

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 47 · Cited by 40

Research works printed but not linked: 41

  1. [1]1. Mudduluru G, Medved F, Grobholz R, et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007;110:1697-707 [DOI] [PubMed] [Google Scholar]
  2. [3]3. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003;22:3712-20 [DOI] [PubMed] [Google Scholar]
  3. [4]4. Yang HS, Matthews CP, Clair T, et al. Tumorigenesis suppressor Pdcd4 down-regulates MAP4K1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 2006;26:1297-306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. [6]6. Nieves-Alicea R, Colburn NH, Simeone AM, Tari AM. Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res Treat. 2009;114:203-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. [7]7. Wang Q, Sun Z, Yang HS. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene. 2008;27:1527-35 [DOI] [PubMed] [Google Scholar]
  6. [8]8. Wang Q, Sun ZX, Allgayer H, Yang HS. Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells. Oncogene. 2010;29:128-38 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. [9]9. Santhanam AN, Baker AR, Hegamyer G, Kirschmann DA, Colburn NH. Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion. Oncogene. 2010;29:3921-32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. [10]10. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005;65:6034-41 [DOI] [PubMed] [Google Scholar]
  9. [11]11. Hilliard A, Hilliard B, Zheng SJ, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol. 2006;177:8095-102 [DOI] [PubMed] [Google Scholar]
  10. [13]13. Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 2003;200:640-6 [DOI] [PubMed] [Google Scholar]
  11. [14]14. Wei NA, Liu SS, Leung TH, et al. Loss of programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Mol Cancer. 2009;8:70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. [16]16. Jin H, Kim TH, Hwang SK, et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle and angiogenesis in lung of K-ras null mice. Mol Cancer Ther. 2006;5:1041-9 [DOI] [PubMed] [Google Scholar]
  13. [17]17. Wei ZT, Zhang X, Wang XY, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci. 2009;100:1408-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. [18]18. Hayashi A, Aishima S, Miyasaka Y, et al. Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: its association with tumor progression and proliferation. Hum Pathol. 2010;41:1507-15 [DOI] [PubMed] [Google Scholar]
  15. [19]19. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501 [DOI] [PubMed] [Google Scholar]
  16. [20]20. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903-10 [DOI] [PubMed] [Google Scholar]
  17. [21]21. Guo Y, Yang K, Harwalkar J, et al. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene. 2005;24:2599-612 [DOI] [PubMed] [Google Scholar]
  18. [22]22. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82-5 [DOI] [PubMed] [Google Scholar]
  19. [23]23. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-62 [DOI] [PubMed] [Google Scholar]
  20. [24]24. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006:re13. [DOI] [PubMed] [Google Scholar]
  21. [25]25. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993;7:1559-71 [DOI] [PubMed] [Google Scholar]
  22. [26]26. Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38:217-22 [DOI] [PubMed] [Google Scholar]
  23. [27]27. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol. 2003;23:4713-27 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. [28]28. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2:339-45 [PubMed] [Google Scholar]
  25. [29]29. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol. 2004;15:177-82 [DOI] [PubMed] [Google Scholar]
  26. [30]30. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499-511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. [31]31. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. [32]32. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110:669-74 [DOI] [PubMed] [Google Scholar]
  29. [33]33. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522-7 [DOI] [PMC free article] [PubMed] [Google Scholar] 34.Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol. 1993;13:7358-63 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. [35]35. Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol. 2004;24:3894-906 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. [37]37. Loh PG, Yang HS, Walsh MA, et al. Structural basis for translational inhibition by the tumour suppressor Pdcd4. EMBO J. 2009;28:274-85 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. [38]38. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol. 1999;31:59-72 [DOI] [PubMed] [Google Scholar]
  33. [39]39. Wedeken L, Ohnheiser J, Hirschi B, Wethkamp N, Klempnauer KH. Association of tumor suppressor protein Pdcd4 with ribosomes is mediated by protein-protein and protein RNA interactions. Genes Cancer. 2010;1:293-301 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. [40]40. Gingras AC, Raught B, Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol. 2004;279:169-97 [DOI] [PubMed] [Google Scholar]
  35. [41]41. Shahbazian D, Roux PP, Mieulet V, et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006;25:2781-91 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. [42]42. Zhang Y, Wang Q, Guo X, Miller R, Guo Y, Yang HS. Activation and up-regulation of translation initiation factor 4B contribute to arsenic-induced transformation. Mol Carcinog. 2011;50:528-38 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. [43]43. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-27 [DOI] [PubMed] [Google Scholar]
  38. [44]44. Lankat-Buttgereit B, Muller S, Schmidt H, Parhofer KG, Gress TM, Goke R. Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Biol Cell. 2008;100:703-15 [DOI] [PubMed] [Google Scholar]
  39. [46]46. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006;314:467-71 [DOI] [PubMed] [Google Scholar]
  40. [47]47. Gray NK, Hentze MW. Regulation of protein synthesis by mRNA structure. Mol Biol Rep. 1994;19:195-200 [DOI] [PubMed] [Google Scholar]
  41. [48]48. Portereiko MF, Lloyd A, Steffen JG, Punwani JA, Otsuga D, Drews GN. AGL80 is required for central cell and endosperm development in arabidopsis. Plant Cell. 2006;18:1862-72 [DOI] [PMC free article] [PubMed] [Google Scholar] Articles from Genes & Cancer are provided here courtesy of Impact Journals, LLC

Authors
Guo, X., Li, W., Wang, Q., & Yang, H.-S.
Affiliations
University of Kentucky (US)
Venue
Genes & Cancer
Published
2011-08-01
Volume
2
Issue
8
Pages
818-828
ISSN
  • 1947-6019 (ISSN-L)
  • 1947-6027
OpenAlex
W2167783295
Cited by
40
References
47
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 2
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • Genes & Cancer (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (R01CA129015)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
PDCD4, Akt activation, cyclin D1, NF-κB, IκB kinase, cell proliferation, tumor suppressor, cyclin D1 promoter, Akt phosphorylation, carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review